Dr. Ron Najafi, CEO of NovaBay, describes MRSA (methicillin-resistant Staphylococcus aureus) as a slow-moving hurricane. "Once the ‘superbug’ hits a community or hospital," asks Dr. Najafi, "are populations ready to deal with it?"
His comment was prompted by the untimely death of college student Chris Steden to the disease, which infects 90,000 Americans in our hospitals every year, with 19,000 deaths reported annually.
The company is working on a compound, NVC-422, which may successfully fight many pathogens including MRSA. S. aureua breeds in the nose and on the skin. NovbaBay’s AgaNase formulation of NVC-422 for nasal applications, is an anti-infective, but not a conventional antibiotic. Topically applied to the lower nasal passage to eliminate colonization of S. aureus, including MRSA, AgaNase rapidly destroys a range of pathogens that include bacteria, yeast, and viruses.
Source: NobaBay Pharmaceuticals